<DOC>
	<DOCNO>NCT02584920</DOCNO>
	<brief_summary>Randomised , double-blind , parallel group study compare PK PD profile HLX01 rituximab ( MabThera® ) patient CD20+ B-cell Lymphoma .</brief_summary>
	<brief_title>A Pharmacokinetic Pharmacodynamic Study Comparing HLX01 And Rituximab Patients With CD20-Positive , B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. age 18 65 year ; 2 . CD20positive nonHodgkin 's lymphoma ( NHL ) ; 3. obtain CR ( complete remission ) CRu ( uncertain complete remisson ) prior therapy ; 4 . ECOG performance status &lt; =1 , expect survival least &gt; = 3 month ; 5 . Peripheral blood lymphocyte count &lt; 5×10^9/L 6. sign inform consent form approve institutional review board respective medical center . 1 . Other invasive malignancy within 5 year except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix ; 2 . Chemotherapy within 1 month ; 3 . Had receive rituximab antiCD20 ( + ) monoclonal antibody treatment within 1 month enrollment ; 4 . Had receive rituximab antiCD20 ( + ) monoclonal antibody treatment 1 month ago ADA ( + ) enrollment ; 5 . Blood concentration Rituximab &gt; 24 μg/ml prior study entry ; 6 . Had receive hematopoitic growth factor within 1 week prior study entry ; 7 . Receipt live/attenuated vaccine within 4 week prior Screening Visit ; 8 . Recent major surgery ( within 8 week prior screen , exclude lymph node biopsy ) ; 9 . Peripheral central nervous system disease ; 10 . Serious hematologic dysfunction ( white blood cell count &lt; 3.0×109/L ; absolute neutrophil count &lt; 1.5×109/L ; platelet count &lt; 100×109/L ; hemoglobin level &lt; 9.0 g/dL ) ; 11 . Hepatic dysfunction ( total bilirubin level &gt; 1.5 × upper limit normal ( ULN ) ; aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) level &gt; 2.0 × ULN ; alkaline phosphatase &gt; 3.0 × ULN ; renal dysfunction ( serum creatinine level &gt; 1.5×ULN ) ; 12 . Abnormal thyroid function ; 13 . Seropositive HIV , HCV antibody ; seropositive hepatitis B virus surface antigen ( HBsAg ) . HBV DNA &gt; 1.0×103copies/ml ; 14 . Serious underlie medical condition , could impair ability patient participate trial ( include limit ongoing active infection , uncontrolled diabetes mellitus , significant cardiac disease , uncontrolled angina , gastric ulcer , active autoimmune disease ) ; 15 . Pregnancy breast feeding . For woman childbearing potential . 16 . History severe allergic reaction anaphylactic reaction biological agent history hypersensitivity component trial drug . 17 . Subjects history alcoholism drug abuse ; 18 . Researchers think fit group .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>